Avior Wealth Management’s ImmunityBio IBRX Stock Holding History

Avior Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-26	Closed	-$139	–	2944
2024 Q1	$139	Buy	+26	New	+$118	﹤0.01%	3039

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Avior Wealth Management's IBRX Position: Q2 2024 in Review

Avior Wealth Management sold out of ImmunityBio (IBRX) in Q2 2024, closing a stake of 26 shares — an estimated $139 sold.

Avior Wealth Management first reported a position in IBRX in Q1 2024 and held it in 1 quarter. The position peaked at $139 in Q1 2024. 193 funds tracked by Wall St. Rank hold IBRX as of Q2 2024.

Avior Wealth Management reported no remaining ImmunityBio position as of Q2 2024 after selling out during the quarter.
Avior Wealth Management sold 26 ImmunityBio shares in Q2 2024, an estimated $139.
Avior Wealth Management first reported a position in ImmunityBio in Q1 2024 and held it in 1 quarter.
Avior Wealth Management's ImmunityBio position peaked at $139 in Q1 2024.
193 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.